Pascal Soriot

Pascal Claude Roland Soriot (born 23 May 1959) is the chief executive officer of the pharmaceutical multinational company AstraZeneca, since October 2012.[2]

Pascal Soriot
Soriot in 2019
Born
Pascal Claude Roland Soriot

(1959-05-23) 23 May 1959[1]
NationalityFrench
EducationÉcole nationale vétérinaire d'Alfort[1]
HEC Paris
OccupationBusinessman
Years active1982–present
TitleCEO, AstraZeneca
Term2012–
SuccessorIncumbent
Children2

In July 2017, it was reported that Soriot would become the next CEO of Israel-based Teva Pharmaceutical Industries, succeeding Erez Vigodman, though this was soon denied.[3][4][5]

Early life

Born in France, his father died when Soriot was 20.[6]

He studied veterinary medicine at the École nationale vétérinaire d'Alfort at Maisons-Alfort in south-east Paris).[1] He later obtained an MBA at HEC Paris.[2]

Career

Roussel Uclaf

In April 1986, he joined Roussel Uclaf (formerly France's second largest pharmaceutical company, until bought by Hoechst AG in 1997) as a salesman in Australia.[1][7] In 1996 he became General Manager of Hoechst Marion Roussel in Australia, moving to Tokyo in April 1997.

Aventis

In 2000 he moved to Aventis in America, becoming chief operating officer of Aventis USA in 2002, which became Sanofi Aventis USA in 2004.

Roche

He joined Roche in 2006. From April 2009 to 2010 he was chief executive of the Roche subsidiary Genentech. He rejoined Roche Pharma AG in 2010 as chief operating officer.[8]

AstraZeneca

In August 2012 he was named as the new chief executive of AstraZeneca,[9] the world's fifth largest pharmaceutical company, when aged 53. He took up the post on 1 October 2012.

In September 2018 he made headlines commenting on his pay of £9.4m in salary and bonuses. 'The truth is I’m the lowest-paid CEO in the whole industry', he said. 'It is annoying to some extent. But at the end of the day it is what it is.'[10]

Personal life

He is married and has two children.[11] He has three brothers, all of whom are doctors.[6]

References
  1. "Pascal Soriot: Leader of the great escape". Financial Times. Retrieved 26 January 2017.
  2. "Executive Profile: Pascal Soriot". Bloomberg. Retrieved 3 April 2015.
  3. Boland, Hannah (14 July 2017). "Pascal Soriot looks set to stay as AstraZeneca chief". The Telegraph – via www.telegraph.co.uk.
  4. Reuters Editorial (14 May 2014). "AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report". Reuters. Retrieved 12 July 2017.
  5. "Israeli newspaper reports that AstraZeneca CEO Pascal Soriot has agreed to take the helm at Teva – ENDPOINTS NEWS". Endpts.com. Retrieved 12 July 2017.
  6. Ralph, Alex (17 May 2019). "A drugs giant that loves to blind rivals with science". The Times. ISSN 0140-0460. Retrieved 17 May 2019.
  7. "Pascal Soriot". Roche.com. Retrieved 26 January 2017.
  8. "AstraZeneca Names Roche's Pascal Soriot as CEO". Bloomberg. Retrieved 6 February 2013.
  9. Rowley, Emma (28 August 2012). "AstraZeneca appoints Roche's Pascal Soriot as new chief". The Telegraph. Retrieved 26 January 2017.
  10. Meddings, Sabah. "Salary size matters, says Astra Zeneca boss on £9.4m" – via www.thetimes.co.uk.
  11. James Ashton (16 May 2014). "Astrazeneca chief Pascal Soriot: I can carry on curing the company, says scientist in £63bn bid battle". Standard.co.uk. Retrieved 26 January 2017.
Business positions
Preceded by
David Brennan		 Chief Executive of AstraZeneca
2012 –		 Succeeded by
Incumbent
Preceded by
 Chief Operating Officer of Hoffmann-La Roche
2010 – 2012		 Succeeded by
Daniel O'Day
Preceded by
 Chief Executive of Genentech
2009 – 2010		 Succeeded by
Ian Clark
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.